Tango Therapeutics
TNGX
21.83
-0.07
-0.32%
Tango Therapeutics
US · TNGX
#2322 by market cap
Listed 1970
21.83
-0.07
-0.32%
Live - 5344 symbols - heartbeat 341s ago
· 2026-10-08 06:07
Pre-market
21.69
-0.64%
After-hours
21.83
0.00%
- Market cap
- 3.68B
- P/E (TTM)i
- -25.99
- P/Bi
- 3.59
- EPSi
- -0.87
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on TNGX?
Anonymous reader poll. Unscientific, not investment advice.
About Tango Therapeutics
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, Antoni Ribas and Barbara Weber in 2017 and is headquartered in Boston, MA.
- Founded
- 2017
- CEO
- Dr. Malte Peters, M.D.
- Employees
- 137
- Headquarters
- Boston, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- tangotx.com
Company profile
- Exchange
- US
- Symbol
- TNGX
- Market-cap rank
- #2322
- Listing date
- 1970-01-01
- Market cap
- 3.68B
- Float cap
- 2.63B
- Shares out
- 168.61M
- Float shares
- 120.67M
Sectors & themes
Quote time 2026-10-08 06:07:34 · For reference only, not investment advice and not tailored to your situation.